Freestone Grove Partners’s Innoviva INVA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.91M Sell
81,846
-9,827
-11% -$212K 0.01% 377
2025
Q4
$1.83M Sell
91,673
-84,748
-48% -$1.65M 0.01% 406
2025
Q3
$3.22M Buy
176,421
+155,598
+747% +$3.03M 0.02% 351
2025
Q2
$418K Buy
20,823
+948
+5% +$18.2K ﹤0.01% 550
2025
Q1
$360K Sell
19,875
-18,950
-49% -$340K ﹤0.01% 448
2024
Q4
$674K Buy
+38,825
New +$746K 0.01% 336

Other funds holding INVA

Freestone Grove Partners's INVA Position: Q1 2026 in Review

Freestone Grove Partners reduced its Innoviva (INVA) stake by 11% in Q1 2026, selling an estimated $212K and leaving 81,846 shares worth $1.91M. The position accounts for 0.01% of the portfolio, ranked #377.

Freestone Grove Partners first reported a position in INVA in Q4 2024 and has held it in 6 quarters since. The position peaked at $3.22M in Q3 2025. 286 funds tracked by Wall St. Rank hold INVA as of Q1 2026.

  • Freestone Grove Partners held 81,846 shares of Innoviva worth $1.91M as of Q1 2026.
  • Freestone Grove Partners sold 9,827 Innoviva shares in Q1 2026, an estimated $212K.
  • Innoviva made up 0.01% of Freestone Grove Partners's portfolio in Q1 2026, its #377 holding.
  • Freestone Grove Partners first reported a position in Innoviva in Q4 2024 and has held it in 6 quarters since.
  • Freestone Grove Partners's Innoviva position peaked at $3.22M in Q3 2025.
  • 286 funds tracked by Wall St. Rank held Innoviva as of Q1 2026.

Based on Freestone Grove Partners's 13F filing for Q1 2026, filed 15 May 2026.